SEC Form 4 · accession 0001493152-26-029484
Nasus Pharma Ltd · NSRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dan Benjamin Teleman
Officer — Chief Executive Officer · Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 7:12 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002029039
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 17, 2026 | P | 6,550 | $3.10 | A | 163,541 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of: (i) 30,696 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days.